| Business Summary | | Xtrana,
Inc.,
formerly
known
as
Biopool
International,
Inc.,
is
engaged
in
the
research,
development,
manufacture,
and
marketing
of
in
vitro
(outside
the
body)
diagnostic
and
nucleic
acid
testing
products.
The
Company
sells
over
100
in
vitro
diagnostic
products
on
a
worldwide
basis
to
hospitals,
clinical
laboratories,
commercial
reference
laboratories,
and
research
institutions
for
use
in
disease
detection
and
prevention.
In
addition,
as
a
result
of
the
merger
it
completed
in
August
2000
with
Xtrana,
Inc.,
the
Company
owns
newly
developed
proprietary
technology
for
the
development
of
nucleic
acid-based
tests
for
use
in
drug
discovery,
detection
of
environmental
and
food
contaminants,
forensics
and
identity
testing,
human
and
animal
diseases,
genetic
predisposition
to
disease,
and
other
applications.
Specific
pathogens
for
which
the
Company
is
currently
developing
tests
include
E.
coli,
Listeria
and
Salmonella
in
food,
Cryptosporidium
and
coliforms
in
water,
and
chlamydia. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Xtrana,
Inc.
is
engaged
in
the
research,
development,
manufacture
and
marketing
of
in
vitro
(outside
the
body)
diagnostic
products
to
hospitals,
clinical
and
commercial
laboratories,
blood
centers
and
research
institutions.
For
the
six
months
ended
6/01,
sales
fell
6%
to
$4.9
million.
Net
loss
totaled
$1.7
million
vs.
an
income
of
$589
thousand.
Results
reflect
lower
European
sales,
lower
profit
margins,
merger-related
expenses
and
increased
R
and
D
spendings. | More
from
Market Guide: Significant
Developments |
| | | Michael
D. Bick,
Chmn./Pres. Timothy
J. Dahltorp,
CEO/CFO Robert
K. Foote,
Secy. Calyon
H. Duke,
VP. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|